TOKYO — German drugmaker Boehringer Ingelheim plans to invest a total of 300 million euros ($346 million) in its plant in Japan from 2023 to 2028 as it moves to make the facility a production base for Asia and Oceania.
The plant, in the country’s northeastern prefecture of Yamagata, currently produces the diabetes and kidney disease treatment drug Jardiance, mainly for the domestic market.
